<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lymphoid Malignancies</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\(', '\)']],
            displayMath: [['$$', '$$'], ['\[', '\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="hematology-myeloid-malignancies.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 83.33%;"></div> <!-- Set percentage dynamically -->
                        </div>
                       <span class="progress-text">Lecture 5 of 6</span> <!-- Update text -->
                    </div>
                    <a href="hematology-wbc-disorders-transfusions.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">Lymphoid Malignancies</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                <!-- START: all -->
                <section id="all" class="content-section" aria-labelledby="section-heading-1">
                    <h2 id="section-heading-1" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">Pathophysiology</h3>
                        <ul>
                            <li>develops from any lymphoid cell blocked at a particular stage of development</li>
                        </ul>
                        <h3 class="subsection-heading">Clinical Features</h3>
                        <ul>
                            <li>see AML</li>
                            <li>50% present with fever</li>
                        </ul>
                        <h3 class="subsection-heading">Diagnosis</h3>
                        <ul>
                            <li>see AML</li>
                            <li>leukemic lymphoblasts lack specific morphological or cytochemical features, therefore diagnosis depends on immunophenotyping</li>
                            <li>immunology (B or T lineage)</li>
                            <li>cytogenetics</li>
                        </ul>
                        <h3 class="subsection-heading">Treatment</h3>
                        <ul>
                            <li>see AML</li>
                            <li>eliminate abnormal clone
                                <ol>
                                    <li>Induction</li>
                                    <li>Consolidation</li>
                                    <li>Intensification</li>
                                    <li>Maintenance</li>
                                    <li>Prophylaxis: CNS with XRT or MTX</li>
                                </ol>
                            </li>
                        </ul>
                        <h3 class="subsection-heading">Prognosis</h3>
                        <ul>
                            <li>depends upon response to initial induction or if remission is achieved following relapse</li>
                            <li>achievement of first remission: 60-90%</li>
                            <li>childhood ALL: 80% long term remission (> 5 years)</li>
                            <li>adult ALL: 30-40% 5 year survival</li>
                        </ul>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Table 13. To Differentiate AML From ALL - Remember Big and Small</caption>
                                <thead>
                                    <tr><th>AML (see Colour Atlas H11)</th><th>ALL (see Colour Atlas H13)</th></tr>
                                </thead>
                                <tbody>
                                    <tr><td>big people (adults)</td><td>small people (kids)</td></tr>
                                    <tr><td>big blasts</td><td>small blasts</td></tr>
                                    <tr><td>lots of cytoplasm</td><td>little cytoplasm</td></tr>
                                    <tr><td>lots of nucleoli (3-5)</td><td>few nucleoli (1-3)</td></tr>
                                    <tr><td>lots of granules and Auer rods</td><td>no granules</td></tr>
                                    <tr><td>big toxicity of treatment</td><td>little toxicity of treatment</td></tr>
                                    <tr><td>big mortality rate</td><td>small mortality rate</td></tr>
                                    <tr><td>myeloperoxidase, sudan black stain</td><td>PAS (periodic acid schiff)</td></tr>
                                    <tr><td>maturation defect beyond myeloblast or promyelocyte</td><td>maturation defect beyond lymphoblast</td></tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>
                <!-- END: all -->

                <!-- START: lymphomas -->
                <section id="lymphomas" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">LYMPHOMAS</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA STAGING</h3>
                        <p><strong>Stage I</strong></p>
                        <ul>
                            <li>involvement of a single lymph node region or extralymphatic organ or site</li>
                        </ul>
                        <p><strong>Stage II</strong></p>
                        <ul>
                            <li>involvement of two or more lymph node regions OR an extralymphatic site and one or more lymph node regions on SAME side of diaphragm</li>
                        </ul>
                        <p><strong>Stage III</strong></p>
                        <ul>
                            <li>involvement of lymph node regions on BOTH sides of the diaphragm</li>
                            <li>may or may not be accompanied by single extralymphatic site or splenic involvement</li>
                        </ul>
                        <p><strong>Stage IV</strong></p>
                        <ul>
                            <li>diffuse involvement of one or more extralymphatic organs including bone marrow</li>
                        </ul>
                        <h4>Subtypes</h4>
                        <ul>
                            <li>A = Absence of B symptoms</li>
                            <li>B = Presence of B symptoms</li>
                        </ul>
                        <h4>B Symptoms</h4>
                        <ul>
                            <li>unexplained fever >38°C</li>
                            <li>unexplained weight loss (>10% of body weight in 6 months)</li>
                            <li>night sweats</li>
                        </ul>

                        <h3 class="subsection-heading">HODGKIN'S DISEASE</h3>
                        <ul>
                            <li>substantial number represents monocloncal B cell disorders</li>
                            <li>bimodal distribution with peaks at the age of 20 years and > 50 years</li>
                        </ul>
                        <h4>Clinical Features</h4>
                        <ul>
                            <li>lymphadenopathy (neck, axilla)</li>
                            <li>B symptoms</li>
                            <li>classical symptoms
                                <ul>
                                    <li>pruritus</li>
                                    <li>painful nodes following alcohol consumption</li>
                                </ul>
                            </li>
                        </ul>
                        <h4>Diagnosis</h4>
                        <ul>
                            <li>nodal biopsy (see Colour Atlas H15)</li>
                            <li>bone marrow biopsy for Reed-Sternberg cell - polynucleated cells derived from B-cells
                                <ul><li>nodular sclerosis is the most common histological subtype</li></ul>
                            </li>
                        </ul>
                        <h4>Work-up</h4>
                        <ul>
                            <li><strong>CBC</strong>
                                <ul>
                                    <li>normocytic normochromic anemia</li>
                                    <li>leukocytosis in 1/3 of patients</li>
                                    <li>eosinophilia</li>
                                    <li>platelet count is normal or increased in early disease but decreased in advanced disease</li>
                                </ul>
                            </li>
                            <li><strong>biochemistry</strong>
                                <ul>
                                    <li>RFTs to assess renal excretion of chemotherapeutics</li>
                                    <li>LFTs to r/o liver involvement</li>
                                    <li>uric acid</li>
                                    <li>ESR to monitor disease progress</li>
                                    <li>Ca<sup>2+</sup>, ALP, phosphate for bone metastasis</li>
                                </ul>
                            </li>
                            <li>chest x-ray to r/o mediastinal masses and lung metastases</li>
                            <li>CT of chest, abdomen and pelvis</li>
                        </ul>
                        <h4>Management</h4>
                        <ul>
                            <li>high cure rate</li>
                            <li>Stage I-II: radiation therapy or chemotherapy plus local field radiation (less risk of second malignancy)</li>
                            <li>Stage III-IV: combination chemotherapy eg. ABVD or MOPP</li>
                            <li>relapse: high dose chemotherapy, bone marrow transplant</li>
                        </ul>
                        <h4>Complications of Treatment</h4>
                        <ul>
                            <li>diminished fertility
                                <ul><li>consider oophoropexy/sperm banking before radiation</li></ul>
                            </li>
                            <li>post-splenectomy sepsis
                                <ul><li>immunize pre-splenectomy</li></ul>
                            </li>
                            <li>hypothyroidism</li>
                            <li>secondary malignancies
                                <ul>
                                    <li>&lt; 2% risk of MDS, AML</li>
                                    <li>usually within 4 years after exposure to alkylating agents and radiation</li>
                                    <li>solid tumours in the radiation fields > 10 years after exposure</li>
                                </ul>
                            </li>
                            <li>accelerated cardiovascular disease</li>
                        </ul>

                        <h3 class="subsection-heading">NON-HODGKIN'S LYMPHOMA</h3>
                        <h4>Clinical Features</h4>
                        <ul>
                            <li>painless superficial lymphadenopathy usually >1 lymph region</li>
                            <li>usually presents as widespread disease</li>
                            <li>constitutional symptoms (fever, weight loss, night sweats) not as common as in Hodgkin's disease</li>
                            <li>cytopenia: anemia +/- neutropenia +/- thrombocytopenia if bone marrow fails</li>
                            <li>abdominal symptoms or signs
                                <ul>
                                    <li>hepatosplenomegaly</li>
                                    <li>retroperitoneal and mesenteric involvement (2nd most common site of involvement)</li>
                                </ul>
                            </li>
                            <li>oropharyngeal involvement in 5-10% with sore throat and obstructive apnea</li>
                        </ul>
                        <h4>Diagnosis</h4>
                        <ul>
                            <li>lymph node biopsy
                                <ul><li>fine needle aspiration occasionally sufficient, core biopsy preferred</li></ul>
                            </li>
                            <li>bone marrow biopsy</li>
                            <li>peripheral blood film sometimes shows lymphoma cells</li>
                        </ul>
                        <h4>Work-Up</h4>
                        <ul>
                            <li><strong>CBC</strong>
                                <ul>
                                    <li>normocytic normochromic anemia</li>
                                    <li>autoimmune hemolytic anemia</li>
                                    <li>advanced disease: thrombocytopenia, neutropenia, and leukoerythroblastic anemia</li>
                                </ul>
                            </li>
                            <li><strong>biochemistry</strong>
                                <ul>
                                    <li>increase in uric acid</li>
                                    <li>abnormal LFTs in liver metastases</li>
                                    <li>elevated LDH (rapidly progressing disease and poor prognostic factor)</li>
                                </ul>
                            </li>
                            <li>chest x-ray + CT for thoracic involvement</li>
                            <li>CT for abdominal and pelvic involvement</li>
                        </ul>
                        <h4>Revised European American lymphoma (REAL) Classification for Subtypes of NHL</h4>
                        <p>several classification systems exist and may be used at different centres</p>
                        <ol>
                            <li>plasma cell disorders</li>
                            <li>Hodgkin's lymphoma</li>
                            <li>indolent lymphoma/leukemia
                                <ul>
                                    <li>good prognosis: median survival 10 years</li>
                                    <li>not curable if stage III/IV</li>
                                    <li>8 subtypes of NHL</li>
                                </ul>
                            </li>
                            <li>aggressive lymphoma/leukemia
                                <ul>
                                    <li>shorter natural history</li>
                                    <li>30-60% cured with intensive combination chemotherapy</li>
                                    <li>5 year survival 50-60%</li>
                                    <li>2 main subtypes of NHL</li>
                                </ul>
                            </li>
                        </ol>
                        <h4>Management of NHL</h4>
                        <ul>
                            <li><strong>localized disease (e.g. GI, brain, bone, head and neck)</strong>
                                <ul>
                                    <li>surgery (if applicable)</li>
                                    <li>radiotherapy to primary site and adjacent nodal areas</li>
                                    <li>adjuvant chemotherapy</li>
                                </ul>
                            </li>
                            <li><strong>indolent lymphoma</strong>
                                <ul>
                                    <li>watchful waiting</li>
                                    <li>radiation therapy</li>
                                    <li>chemotherapy</li>
                                </ul>
                            </li>
                            <li><strong>aggressive lymphoma</strong>
                                <ul>
                                    <li>combination chemotherapy</li>
                                    <li>aggressive consolidation with marrow or stem cell support</li>
                                </ul>
                            </li>
                        </ul>
                        <h4>NHL Complications</h4>
                        <ul>
                            <li>hypersplenism</li>
                            <li>infection</li>
                            <li>autoimmune hemolytic anemia and thrombocytopenia</li>
                            <li>vascular obstruction (from enlarged nodes)</li>
                            <li>Note: never give live vaccines e.g. MMR and oral polio</li>
                        </ul>
                        <h4>Indicators of Poor Prognosis</h4>
                        <ul>
                            <li>>60 years old</li>
                            <li>poor response to therapy</li>
                            <li>multiple nodal regions</li>
                            <li>elevated LDH</li>
                            <li>>5 cm nodes</li>
                            <li>previous history of low grade disease or AIDS</li>
                        </ul>
                    </div>
                </section>
                <!-- END: lymphomas -->
                
                <!-- START: b-cell-proliferations -->
                <section id="b-cell-proliferations" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">MALIGNANT CLONAL PROLIFERATIONS OF B CELLS</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)</h3>
                        <ul>
                            <li>indolent disease characterized by the clonal malignancy of poorly functioning B cells</li>
                            <li>accumulation of neoplastic lymphocytes in blood, bone marrow, lymph nodes and spleen</li>
                            <li>most common leukemia in western world</li>
                            <li>mainly older patients</li>
                            <li>up to 60% asymptomatic</li>
                            <li>9 year median survival, but varies greatly</li>
                        </ul>
                        <h4>Investigations</h4>
                        <ul>
                            <li>absolute lymphocytosis >5.0 x 10<sup>9</sup>/L (usually >10.0 x 10<sup>9</sup>/L)</li>
                            <li>lymphocytes small and mature</li>
                            <li>smudge cells (see Colour Atlas H12)</li>
                            <li>diffuse or focal infiltration of marrow by lymphocytes</li>
                        </ul>
                        <h4>Complications</h4>
                        <ul>
                            <li>bone marrow failure</li>
                            <li>bulky lymphadenopathy</li>
                            <li>hypersplenism - immune hemolytic anemia</li>
                            <li>immune thrombocytopenia</li>
                            <li>hypogammaglobinemia</li>
                            <li>monoclonal gammopathy (often IgM)</li>
                            <li>hyperuricemia with treatment</li>
                            <li>transformation to histiocytic lymphoma</li>
                        </ul>
                        <h4>Management</h4>
                        <p>the gentlest treatment that will control symptoms</p>
                        <ul>
                            <li>observation if early, stable, asymptomatic</li>
                            <li>intermittent chlorambucil</li>
                            <li>corticosteroids</li>
                            <li>radiotherapy</li>
                            <li>chemotherapy</li>
                        </ul>
                        <p>no cure</p>
                        
                        <h3 class="subsection-heading">PLASMA CELL MYELOMA (MULTIPLE MYELOMA)</h3>
                        <p>monoclonal malignancy of plasma cells engaged in the production of a specific protein (paraprotein) characterized by replacement of bone marrow and bone destruction incidence: 3 per 100000 increasing frequency with age the protein produced is monoclonal i.e. one class of heavy chains and one type of light chains ("M" protein) light chains only: 15% (light chain disease) IgD (1%) and IgE are rare</p>
                        <h4>Clinical Features</h4>
                        <ul>
                            <li>onset between 40-70 years</li>
                            <li>bone pain, tenderness, deformity</li>
                            <li>weakness, fatigue (due to anemia)</li>
                            <li>weight loss, night sweats with advanced disease</li>
                            <li>abnormal bleeding (epistaxis, purpura)</li>
                            <li>infection eg. pneumococcal diseases</li>
                            <li>renal failure</li>
                            <li>on exam: pallor, bone deformity, pathologic fractures, bone tenderness, hepato/splenomegaly, petechiae and purpura</li>
                        </ul>
                        <h4>Laboratory Features</h4>
                        <ul>
                            <li><strong>peripheral blood film (see Colour Atlas H14)</strong>
                                <ul>
                                    <li>rouleaux</li>
                                    <li>rare plasma cells</li>
                                    <li>normocytic anemia, thrombocytopenia, leukopenia</li>
                                </ul>
                            </li>
                            <li><strong>bone marrow</strong>
                                <ul>
                                    <li>focal or diffuse increase in plasma cells (see Colour Atlas H9)</li>
                                    <li>primitive plasma cells</li>
                                </ul>
                            </li>
                            <li><strong>biochemistry</strong>
                                <ul>
                                    <li>hypercalcemia (N/V, apathy, weakness, polydipsia, polyuria)</li>
                                    <li>increased creatinine</li>
                                    <li>increased ESR</li>
                                    <li>narrow anion gap (myeloma protein is a cation)</li>
                                </ul>
                            </li>
                            <li>monoclonal protein on serum protein electrophoresis</li>
                            <li>heavy chain and light chain types identified by serum immunoelectrophoresis</li>
                            <li>decreased normal immunoglobulins</li>
                            <li>urine electrophoresis (Bence-Jones protein, a light chain dimer)</li>
                        </ul>
                        <h4>Diagnosis</h4>
                        <ul>
                            <li>bone pain, anemia, increased ESR or increased rouleaux suggests myeloma</li>
                            <li>classic diagnostic triad: must show increased numbers of atypical immature plasma cells
                                <ol>
                                    <li>greater than 10% abnormal plasma cells in bone marrow</li>
                                    <li>lytic bone lesions</li>
                                    <li>monoclonal protein spike in serum or urine</li>
                                </ol>
                            </li>
                        </ul>
                        <h4>Complications</h4>
                        <ul>
                            <li><strong>bone abnormalities</strong>
                                <ul>
                                    <li>osteoporosis, pathological fractures - common due to osteoclastic activating factor and PTHrp</li>
                                    <li>lytic lesions are classical (skull, spine, proximal long bones, ribs)</li>
                                    <li>osteoclast activating factor (hypercalcemia, normal ALP)</li>
                                </ul>
                            </li>
                            <li><strong>renal failure secondary to</strong>
                                <ul>
                                    <li>myeloma kidney (intratubular deposition of light chains)</li>
                                    <li>hypercalcemic nephropathy</li>
                                    <li>pyelonephritis</li>
                                    <li>amyloidosis from chronic inflammation</li>
                                    <li>obstructive uropathy</li>
                                    <li>renal infiltration by plasma cells</li>
                                    <li>hyperuricemia</li>
                                    <li>hyperviscosity compromising renal blood flow</li>
                                </ul>
                            </li>
                            <li>recurrent bacterial infections</li>
                            <li>anemia</li>
                            <li>hyperviscosity syndrome (caused by M protein)</li>
                            <li>amyloidosis (CHF, nephrotic syndrome, joint pain, carpal tunnel syndrome)</li>
                            <li>transformation to acute leukemia</li>
                        </ul>
                        <h4>Management</h4>
                        <ul>
                            <li>melphalan, cyclophosphamide or other alkylating agents</li>
                            <li>corticosteroids</li>
                            <li>radiotherapy to local painful lesions</li>
                            <li>bisphosphonates</li>
                            <li>follow serum or urine M protein as indicator of response</li>
                            <li>early identification and treatment of complications</li>
                            <li>treatment of renal failure
                                <ul>
                                    <li>hydration</li>
                                    <li>corticosteroids</li>
                                    <li>plasmapheresis</li>
                                </ul>
                            </li>
                            <li>autologous stem cell transplant</li>
                            <li>thalidomide</li>
                        </ul>
                        <h4>Prognosis</h4>
                        <p>median survival 24-30 months</p>

                        <h3 class="subsection-heading">LIGHT CHAIN DISEASE</h3>
                        <ul>
                            <li>plasma cells produce only light chains</li>
                            <li>15% of patients with myeloma</li>
                            <li><strong>diagnosis</strong>
                                <ul>
                                    <li>urine immunoelectrophoresis</li>
                                    <li>serum studies often non-diagnostic as light chains can pass through glomerulus</li>
                                </ul>
                            </li>
                            <li>renal failure a MAJOR problem</li>
                            <li>prognosis: survival kappa > lambda light chains</li>
                        </ul>
                        
                        <h3 class="subsection-heading">MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE (BENIGN MONOCLONAL GAMMOPATHY)</h3>
                        <ul>
                            <li>incidence: 0.15% in general population, 3% of people > 70 years of age</li>
                            <li><strong>diagnosis</strong>
                                <ul>
                                    <li>exclude myeloma</li>
                                    <li>&lt;10% plasma cells in bone marrow</li>
                                    <li>no rise in the M protein with time</li>
                                </ul>
                            </li>
                            <li>10% of patients develop multiple myeloma each year in the first 3 years</li>
                        </ul>

                        <h3 class="subsection-heading">MACROGLOBULINEMIA OF WALDENSTROM</h3>
                        <ul>
                            <li>uncontrollable proliferation of lymphoplasmacytoid cells (a hybrid of lymphocytes and plasma cells)</li>
                            <li>monoclonal IgM para protein is produced</li>
                            <li>symptoms: weakness, fatigue, bleeding (oronasal), recurrent infections, dyspnea, CHF, weight loss, neurological symptoms peripheral neuropathy, cerebral dysfunction)</li>
                            <li>signs: pallor, splenomegaly, hepatomegaly, lymphadenopathy, retinal lesions</li>
                            <li>bone marrow shows plasmacytoid lymphocytes</li>
                            <li>bone lesions usually not present</li>
                            <li>cold hemagglutinin disease possible</li>
                            <li>normocytic anemia, rouleaux, high ESR if hyperviscosity not present</li>
                            <li>watch for hyperviscosity syndrome</li>
                        </ul>

                        <h3 class="subsection-heading">MACROGLOBULINEMIA-HYPERVISCOSITY SYNDROME</h3>
                        <h4>Clinical Features</h4>
                        <ul>
                            <li>hypervolemia causing: CHF, headache, lethargy, dilutional anemia</li>
                            <li>CNS symptoms: headache, vertigo, ataxia, stroke</li>
                            <li>retina shows venous engorgement and hemorrhages</li>
                            <li>bleeding diathesis
                                <ul><li>due to impaired platelet function, absorption of soluble coagulation factors e.g. nasal bleeding, oozing gums</li></ul>
                            </li>
                            <li>ESR usually very low</li>
                        </ul>
                        <h4>Management</h4>
                        <ul>
                            <li>chlorambucil or melphalan</li>
                            <li>corticosteroids</li>
                            <li>plasmapheresis for hyperviscosity</li>
                        </ul>
                        <div class="table-container">
                             <table class="content-table">
                                <caption>Table 14. Characteristics of B Cell Malignant Proliferation</caption>
                                <thead>
                                    <tr><th></th><th>CLL</th><th>Macroglobulinemia</th><th>Myeloma</th></tr>
                                </thead>
                                <tbody>
                                    <tr><td>Cell Type</td><td>lymphocyte lymphocyte</td><td>plasmacytoid</td><td>plasma cell</td></tr>
                                    <tr><td>Protein</td><td>IgM if present</td><td>IgM</td><td>IgG, A, D or E</td></tr>
                                    <tr><td>Lymph Nodes</td><td>very common</td><td>common</td><td>rare</td></tr>
                                    <tr><td>Bone Lesions</td><td>rare</td><td>rare</td><td>common</td></tr>
                                    <tr><td>Hypercalcemia</td><td>rare</td><td>rare</td><td>common</td></tr>
                                    <tr><td>Renal failure</td><td>rare</td><td>rare</td><td>common</td></tr>
                                    <tr><td>Immunoglobulin Autoimmune Complications</td><td>common</td><td>infrequent</td><td>rare</td></tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>
                <!-- END: b-cell-proliferations -->
                
                <!-- START: bmt -->
                <section id="bmt" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">BONE MARROW TRANSPLANTATION</span>
                    </h2>
                    <div class="content-card">
                        <p>allows even more intensive therapy for hematologic malignancies high doses of chemo +/- whole body radiation "marrow rescue"</p>
                        <ul>
                            <li>autologous: from self</li>
                            <li>allogeneic: HLA identical sibling (donor must be < 55 years)</li>
                        </ul>
                        <p><strong>complications</strong></p>
                        <ul>
                            <li>cytopenias - especially neutropenia and thrombocytopenia</li>
                            <li>infections - especially opportunistic</li>
                            <li>drug toxicity</li>
                        </ul>
                    </div>
                </section>
                <!-- END: bmt -->
                
                <!-- START: tumor-lysis-syndrome -->
                <section id="tumor-lysis-syndrome" class="content-section" aria-labelledby="section-heading-5">
                    <h2 id="section-heading-5" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">TUMOUR LYSIS SYNDROME</span>
                    </h2>
                    <div class="content-card">
                        <p>more common in diseases with large tumour burden and high proliferative rate (high grade lymphoma, leukemia)</p>
                        <p><strong>metabolic abnormalities</strong></p>
                        <ul>
                            <li>hyperuricemia</li>
                            <li>hyperkalemia</li>
                            <li>hyperphosphatemia</li>
                            <li>hypocalcemia</li>
                        </ul>
                        <p><strong>complications</strong></p>
                        <ul>
                            <li>lethal cardiac arrhythmia</li>
                            <li>acute renal failure</li>
                        </ul>
                        <p><strong>Management</strong></p>
                        <ul>
                            <li><strong>prevention</strong>
                                <ul>
                                    <li>aggressive IV hydration</li>
                                    <li>alkalinization of the urine</li>
                                    <li>allopurinol</li>
                                    <li>correction of pre-existing metabolic abnormalities</li>
                                </ul>
                            </li>
                            <li>dialysis</li>
                        </ul>
                    </div>
                </section>
                <!-- END: tumor-lysis-syndrome -->
            </main>

            <!-- Bottom Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="hematology-myeloid-malignancies.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 83.33%;"></div> <!-- Set percentage dynamically -->
                        </div>
                       <span class="progress-text">Lecture 5 of 6</span> <!-- Update text -->
                    </div>
                    <a href="hematology-wbc-disorders-transfusions.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>